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Abstract
Background: Holmes’ tremor is characterized by a combination of rest, postural, and kinetic tremor that is presumably caused by interruption of cerebello-
thalamo-cortical and nigrostriatal pathways. Medical treatment remains unsatisfactory.
Case Report: A 16-year-old girl presented with Holmes’ tremor caused by a transient midbrain abnormality on magnetic resonance imaging (MRI). To explore
the discrepancy between persistent tremor and resolved MRI changes, we performed dopamine transporter single-photon emission computed tomography (DaT-
SPECT) with a 123I-ioflupane that revealed nearly absent DaT binding in the right striatum. Levodopa dramatically improved the tremor.
Discussion: This is only the second report of a transient midbrain MRI abnormality disrupting nigrostriatal pathways. The case highlights the sometimes limited
sensitivity of morphologic imaging for identifying the functional consequences of tissue damage and confirms that DaT imaging may serve as a predictor for
levodopa responsiveness in Holmes’ tremor.
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Introduction
Holmes’ tremor, also known as rubral or midbrain tremor, is
characterized by a low-frequency rest tremor that is accentuated by
posture and movement.
1
Clinical and neuroimaging findings suggest
interruption of cerebello-thalamo-cortical and dopaminergic nigros-
triatal pathways as underlying mechanisms.
2,3
Knowledge about
Holmes’ tremor and its therapeutic response is based on case reports












Here we present the case of a 16-year-old female who was admitted
in February 2013 with left-sided stiffness and shaking of her left hand.
Three months earlier she had been infected with the Epstein–Barr
virus and had viral flu just before symptom onset. Magnetic resonance
imaging (MRI) of the brain revealed a single gadolinium-enhancing
lesion in the right upper cerebral peduncle extending rostrally to
the thalamus, which led to an inflammatory demyelinating process
being suspected (Figure 1A). Whole-spine MRI findings and an
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ophthalmological assessment were unremarkable. Cerebrospinal fluid
examination showed two oligoclonal bands. Cell count, glucose, total
protein, and lactate were normal. Methylprednisolone (1000 mg/day)
was administered for 3 days without clear clinical benefit, although a
marked improvement was noted on MRI. One month later she was
readmitted with a combination of marked rest, postural, and action
tremor; mild dystonic posturing of the left hand; moderately increased
left-sided muscle tone and brisk reflexes; and a spastic gait (Video
Segment 1). Another trial of methylprednisolone (1,000 mg/day) was
administered for 5 days without clinical benefit. Symptomatic
treatment for the disabling tremor was refused.
She presented as clinically unchanged to our movement disorders
clinic in July 2013. Follow-up MRI taken 1 month earlier (Figure 1B)
had shown almost complete remission of the lesion; a slightly smaller
red nucleus on the right side and a small hyperintense area in the right
substantia nigra were the only discrete residual changes on T2-
weighted imaging. Propranolol was started (up to 80 mg/day) with
only mild benefit. To further explore the discrepancy between her
persistent clinical symptoms and nearly normal MRI, we performed
dopamine transporter single-photon emission computed tomography
(DaT-SPECT) with 123I-ioflupane and found nearly absent DaT
binding in the right striatum compatible with ipsilateral nigrostriatal
pathway disconnection (Figure 1C). Levodopa was introduced (up to
300 mg/day) and substantially improved all tremor components
(Video Segment 2). Her symptoms further improved in the following 6
months, with tremor only mildly present during movement (Video
Segment 3). Her gait was normalized except for reduced arm swing on
the left, and a neurological status assessment revealed mildly increased
muscle tone and brisk reflexes on the left side. Levodopa was slowly
reduced to 150 mg/day. Brain MRI 11 months after symptom onset
was unchanged with no new visible lesions.
Discussion
Holmes’ tremor is a symptomatic tremor that typically appears after
a variable delay following midbrain or thalamic lesioning. There is no
evidence of spontaneous remission in patients with static lesions, and
pharmacological treatment is usually unsatisfactory. The pathophy-
siologic basis seems to be interruption of the nigrostriatal and
cerebello-thalamic pathways combined with maladaptive neuroplasti-
city. This complex mechanism may account for the variable treatment
responses to pharmacotherapy. Several functional neuroimaging
techniques have revealed neurochemical abnormalities of the nigros-
triatal system in some but not all patients. Abnormal 18F-fluorodopa
uptake was reported in six patients who developed contralateral tremor
after experiencing upper peduncular lesions.
11
Reduced or abolished
DaT binding was found in patients with Holmes’ tremor following








Bilateral DaT binding reduction was found in a patient with
Holmes’ tremor after thalamic hemorrhage; increased tracer uptake
3 years later was interpreted as partial regeneration of the nigrostriatal
system and corresponded with clinical improvement.
13
In our patient, abolished DaT binding in the right striatum was
found despite an almost complete resolution of the midbrain MRI
abnormality. This indicates a profound disruption of the nigrostriatal
pathways despite apparent tissue regeneration, similar to the
description of abnormal DaT-SPECT in a patient who developed
Holmes’ tremor following a regressive midbrain lesion due to cerebral
toxoplasmosis.
9
This highlights the sometimes limited sensitivity of
morphologic imaging in detecting the functional consequences of tissue
damage.
Levodopa responsiveness has been suggested as a marker of
nigrostriatal involvement, and DaT imaging findings may predict
levodopa responsiveness in patients with Holmes’ tremor.
14
In
accordance with this hypothesis, the introduction of levodopa led to
significant clinical improvement. This is only the second report of a
transient midbrain MRI abnormality disrupting nigrostriatal path-
ways.
9
One may speculate that in such instances, nigrostriatal
pathways may regenerate or functionally recover to some extent.
This may explain why the patient’s tremor continued to improve
Figure 1. MRI Findings. (A) Baseline: left, transversal FLAIR image; right, transverse T1-weighted image. A 1.160.961.0-cm gadolinium-enhancing lesion in
the right upper cerebral peduncle with perifocal edema is shown. (B) Follow-up MRI after 4 months: left, only a slightly smaller right red nucleus compared to the
left, and a small hyperintensity in the area of the right substantia nigra indicating discrete residual changes on T2-weighted imaging; right, complete remission on
contrast-enhanced T1-weighted MRI. (C) DaT-SPECT 5 months after symptom onset shows nearly absent DaT binding in the right striatum. Abbreviations: DaT-
SPECT, Dopamine Transporter Single-photon Emission Computed Tomography; FLAIR, Fluid-attenuated Inversion Recovery; MRI, Magnetic Resonance
Imaging.
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despite a levodopa dosage reduction. However, in the only comparable
case described in the literature, discontinuation of the dopaminergic
agent after 1 year was followed by tremor reappearance.
9
Follow-up
DaT-SPECT would have shed light on this but was refused by our
patient.
In a case series of six patients with Holmes’ tremor, only one showed
mild interhemispheric differences regarding DaT uptake and
responded moderately to levodopa.
14
It therefore remains debatable
whether nigrostriatal damage is crucial for the phenomenology of this
tremor type. Holmes’ tremor may cover a heterogeneous spectrum of
tremors with similar phenomenologies but different pathophysiologies.
It is thus unlikely that clinical grounds alone are sufficient for
predicting responsiveness to levodopa; the case reported here confirms
that functional imaging studies should be considered in the clinical
work-up of these patients.
14
It therefore appear that nigrostriatal damage is not crucial for the
phenomenology of Holmes’ tremor. This tremor syndrome has
multiple etiologies and variable pathophysiology; it does not always
involve a nigrostriatal dopaminergic deficiency. Holmes’ tremor
frequently does not respond to levodopa or other dopaminergic
agonists, and the case reported here lends further support to the notion
that striatal dopaminergic imaging studies may identify patients who
are more likely to respond.
13
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